치료 저항성 조현병의 이해와 치료

키워드

참고문헌 (44)

1. Howes OD, "Schizophrenia : an integrated sociodevelopmental-cognitive model", Lancet, 383, pp.1677~1687 (2014)
2. López-Muñoz F, "History of the discovery and clinical introduction of chlorpromazine", Ann Clin Psychiatry, 17, pp.113~135 (2005)
3. Rössler W, "Size of burden of schizophrenia and psychotic disorders", Eur Neuropsychopharmacol, 15, pp.399~409 (2005)
4. Claghorn J, "The risks and benefits of clozapine versus chlorpromazine", J Clin Psychopharmacol, 7, pp.377~384 (1987)
5. Lehman AF, "Practice guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
6. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP)Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
7. Howes OD, "Treatment-resistant schizophrenia : treatment response and resistance in psychosis(TRRIP)working group consensus guidelines on diagnosis and terminology", Am J Psychiatry, 174, pp.216~229 (2017)
8. Royal Australian, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders", Aust N Z J Psychiatry, 39, pp.1~30 (2005)
9. Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 25, pp.567~620 (2011)
10. Verma S, "Ministry of Health clinical practice guidelines: schizophrenia", Singapore Med J, 52, pp.521~525 (2011)
11. McCutcheon R, "Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms", J Psychopharmacol, 29, pp.892~897 (2015)
12. Kane JM, "Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies", World Psychiatry, 12, pp.216~226 (2013)
13. Velligan DI, "Relationships among subjective and objective measures of adherence to oral antipsychotic medications", Psychiatr Serv, 58, pp.1187~1192 (2007)
14. Jónsdóttir H, "Medication adherence in outpatients with severe mental disorders : relation between self-reports and serum level", J Clin Psychopharmacol, 30, pp.169~175 (2010)
15. Byerly M, "A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia", Psychiatry Res, 133, pp.129~133 (2005)
16. Seeman P, "Antipsychotic drugs : direct correlation between clinical potency and presynaptic action on dopamine neurons", Science, 188, pp.1217~1219 (1975)
17. Madras BK, "History of the discovery of the antipsychotic dopamine D2 receptor : a basis for the dopamine hypothesis of schizophrenia", J Hist Neurosci, 22, pp.62~78 (2013)
18. Kapur S, "Does fast dissociation from the dopamine d(2)receptor explain the action of atypical antipsychotics? : a new hypothesis", Am J Psychiatry, 158, pp.360~369 (2001)
19. Cross AJ, "3H-flupenthixol binding in post-mortem brains of schizophrenics : evidence for a selective increase in dopamine D2 receptors", Psychopharmacology(Berl), 74, pp.122~124 (1981)
20. Howes OD, "The nature of dopamine dysfunction in schizophrenia and what this means for treatment", Arch Gen Psychiatry, 69, pp.776~786 (2012)
21. -DOPA PET imaging study, "Am J Psychiatry", 2011, 1311~1317
22. Demjaha A, "Dopamine synthesis capacity in patients with treatment-resistant schizophrenia", Am J Psychiatry, 169, pp.1203~1210 (2012)
23. DOPA PET study, "Neuropsychopharmacology", 2017, 941~950
24. Mouchlianitis E, "Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive", Schizophr Bull, 42, pp.744~752 (2016)
25. Duncan GE, "Metabolic mapping of the rat brain after subanesthetic doses of ketamine : potential relevance to schizophrenia", Brain Res, 787, pp.181~190 (1998)
26. Veerman SR, "The glutamate hypothesis : a pathogenic pathway from which pharmacological interventions have emerged", Pharmacopsychiatry, 47, pp.121~130 (2014)
27. Agid O, "Early use of clozapine for poorly responding first-episode psychosis", J Clin Psychopharmacol, 27, pp.369~373 (2007)
28. Stansley BJ, "The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia", Curr Opin Pharmacol, 38, pp.31~36 (2018)
29. Shim SS, "Potentiation of the NMDA receptor in the treatment of schizophrenia : focused on the glycine site", Eur Arch Psychiatry Clin Neurosci, 258, pp.16~27 (2008)
30. Asenjo Lobos C, "Clozapine versus other atypical antipsychotics for schizophrenia", Cochrane Database Syst Rev, 11, pp.CD006633~ (2010)
31. Nielsen J, "Optimizing clozapine treatment", Acta Psychiatr Scand, 123, pp.411~422 (2011)
32. Kapur S, "Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action", J Psychiatry Neurosci, 25, pp.161~166 (2000)
33. Burki HR, "Effects of fluperlapine on dopaminergic systems in rat brain", Psychopharmacology(Berl), 89, pp.77~84 (1986)
34. Saller CF, "Seroquel : biochemical profile of a potential atypical antipsychotic", Psychopharmacology(Berl), 112, pp.285~292 (1993)
35. Barbui C, "Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial", J Clin Psychopharmacol, 31, pp.266~273 (2011)
36. Taylor DM, "Augmentation of clozapine with a second antipsychotic-a meta-analysis", Acta Psychiatr Scand, 125, pp.15~24 (2012)
37. Barnes TRE, "Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial", Ther Adv Psychopharmacol, 8, pp.185~197 (2018)
38. Wang J, "Sulpiride augmentation for schizophrenia", Cochrane Database Syst Rev, 1, pp.CD008125~ (2010)
39. Fleischhacker WW, "Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial", Int J Neuropsychopharmacol, 13, pp.1115~1125 (2010)
40. Parsons CG, "Memantine as an example of a fast, voltagedependent, open channel N-methyl-D-aspartate receptor blocker", Methods Mol Biol, 403, pp.15~36 (2007)
41. Areosa SA, "Memantine for dementia", Cochrane Database Syst Rev, 20, pp.CD003154~ (2005)
42. Veerman SR, "Memantine augmentation in clozapine-refractory schizophrenia: a randomized, doubleblind, placebo-controlled crossover study", Psychol Med, 46, pp.1909~1921 (2016)
43. Veerman SR, "Adjunctive memantine in clozapine-treated refractory schizophrenia : an open-label 1-year extension study", Psychol Med, 47, pp.363~375 (2017)
44. Tiihonen J, "The efficacy of lamotrigine in clozapine-resistant schizophrenia : a systematic review and meta-analysis", Schizophr Res, 109, pp.10~14 (2009)

관련 논문AI추천